Danaher(US:DHR)2025-04-22 10:08Financial Performance - Net earnings for Q1 2025 were $954 million, or $1.32 per diluted common share, with non-GAAP adjusted diluted net earnings per common share at $1.88[8] - Revenues decreased by 1.0% year-over-year to $5.7 billion, while non-GAAP core revenue remained flat[8] - Operating cash flow was reported at $1.3 billion, and non-GAAP free cash flow was $1.1 billion[8] - The company reported a gross profit of $3.511 billion for Q1 2025, compared to $3.487 billion in Q1 2024[14] - Operating profit for Q1 2025 was $1.274 billion, down from $1.312 billion in the same period last year[14] - Net cash provided by operating activities for the three-month period ended March 28, 2025, was $1,299 million, down from $1,739 million in the prior year[24] - Free cash flow (non-GAAP) for the three-month period ended March 28, 2025, was $1,060 million, compared to $1,448 million in the same period last year[24] Revenue Growth Expectations - For Q2 2025, the company anticipates non-GAAP core revenue growth in the low-single digits year-over-year[4] - The full year 2025 revenue growth expectation is approximately 3% year-over-year[4] - The company forecasts low-single digit core sales growth for the three-month period ending June 27, 2025, and approximately 3.0% growth for the year ending December 31, 2025[23] Earnings Guidance - The company initiated full year adjusted diluted net earnings per common share guidance in the range of $7.60 to $7.75[4] - Adjusted diluted net earnings per common share are projected to be between $7.60 and $7.75 for the year ending December 31, 2025[23] Segment Performance - Total sales for the company declined by 1.0% compared to the same period in 2024, with biotechnology segment sales growing by 6.0%[22] - Core sales growth (non-GAAP) for the biotechnology segment was 7.0%, while life sciences and diagnostics segments experienced declines of 4.0% and 1.5%, respectively[22] Strategic Focus - The company highlighted continued momentum in bioprocessing and better-than-expected respiratory demand in molecular diagnostics[2] - The company emphasized its strong balance sheet and resilient portfolio as key differentiators for 2025 and beyond[2] Cash Flow and Financing - Total cash used in financing activities was $1,255 million for the three-month period ended March 28, 2025, compared to $133 million in the prior year[24] - The company defines free cash flow as operating cash flows minus capital expenditures plus proceeds from capital disposals, highlighting its ability to generate cash for growth and investments[24] Non-GAAP Measures - The company emphasizes the importance of non-GAAP measures to provide a clearer view of its operating and financial performance, excluding items like amortization of intangible assets and restructuring charges[25][26] - The company excludes the impact of currency translation and acquisitions from core sales to better identify underlying growth trends[26][27]